Related Experiment Videos
Cardiovascular effects of an immunosuppressive agent cyclosporin A
1Department of General Medicine, Gunma University School of Medicine, Maebashi, Gunma, Japan.
Insights
Cyclosporin A (CsA) is a common immunosuppressant but can cause cardiovascular issues like hypertension and diabetes. This review explores CsA's cardiovascular effects, including its impact on cardiac hypertrophy and tumors.
Area of Science:
- Immunology
- Cardiology
- Pharmacology
Background:
- Cyclosporin A (CsA) is a vital immunosuppressant for organ transplantation and autoimmune diseases.
- CsA treatment is linked to adverse cardiovascular events, including hypertension, hyperlipidemia, and diabetes.
- These conditions increase cardiovascular morbidity in transplant recipients.
Purpose of the Study:
- To review recent findings on the cardiovascular effects of Cyclosporin A.
- To examine the role of CsA in cardiac hypertrophy and related signaling pathways.
- To discuss CsA's impact on cytokine production in cardiac tumors.
Main Methods:
- Review of recent scientific literature on Cyclosporin A's cardiovascular effects.
- In vivo and in vitro studies investigating calcineurin signaling in cardiac hypertrophy.
- Cell culture experiments assessing CsA's effect on cytokine production in cardiac myxoma cells.
Main Results:
- Cyclosporin A is associated with iatrogenic cardiovascular complications post-transplantation.
- CsA's calcineurin inhibition plays a role in signal transduction pathways of cardiac hypertrophy.
- CsA demonstrated an inhibitory effect on cytokine production by cardiac myxoma cells.
Conclusions:
- Cyclosporin A, while essential for transplantation, poses significant cardiovascular risks.
- Understanding CsA's cardiovascular effects is crucial for managing transplant recipients.
- Further research into CsA's mechanisms in cardiac conditions and tumors is warranted.
Abstract:
Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in transplant recipients. Recently, the calcineurin inhibitor CsA has been employed in vivo and in vitro to examine the role of calcineurin in the signal transduction leading to cardiac hypertrophy. A cell culture study demonstrated the inhibitory effect of CsA on cytokine production by cardiac myxoma cells, the most common primary tumor of the heart. This review discusses recent data on the cardiovascular effects of CsA.